PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D change of 20.47% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
-32.93%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-386.54%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
2.68%
Operating expenses growth 50-90% of Biotechnology median of 5.26%. Mohnish Pabrai would examine discipline.
2.68%
Total costs growth below 50% of Biotechnology median of 6.29%. Joel Greenblatt would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
-2.70%
EBITDA decline while Biotechnology median is -0.26%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Operating income decline while Biotechnology median is -2.55%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-2.79%
Pre-tax income decline while Biotechnology median is -0.12%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.79%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
1.20%
EPS change of 1.20% versus flat Biotechnology. Walter Schloss would verify quality.
2.99%
Diluted EPS change of 2.99% versus flat Biotechnology. Walter Schloss would verify quality.
3.80%
Share count reduction below 50% of Biotechnology median of 0.05%. Jim Chanos would check for issues.
6.10%
Diluted share reduction below 50% of Biotechnology median of 0.03%. Jim Chanos would check for issues.